The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Paclitaxel (TLX) and cetuximab (CTX) combination efficiency after failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma (RMHNSCC).
P. Ceruse
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono
E. Lavergne
No relevant relationships to disclose
G. Buiret
No relevant relationships to disclose
B. Pham
No relevant relationships to disclose
S. Chabaud
No relevant relationships to disclose
B. Favier
No relevant relationships to disclose
D. Girodet
No relevant relationships to disclose
P. Zrounba
No relevant relationships to disclose
J. Fayette
No relevant relationships to disclose